The US National Institutes of Health (NIH) has awarded a five-year, $2.2m grant to researchers to study biomarkers in the blood of traumatic brain injury (TBI) patients. The research team includes Emory School of Medicine, Banyan Biomarkers, the Medical University of South Carolina, the University of Pittsburgh and the University of Michigan, and it will study patients enrolled in the experimental clinical treatment (ProTECT) III trial, which is assessing the efficacy of progesterone in the treatment of TBI. The multi-site NIH-sponsored clinical study enrolled 1,140 TBI patients across 17 centres nationwide. Banyan Biomarkers Business Development and Analytical Service Department director Andreas Jeromin said the biomarkers will have the potential to improve the ability to diagnose a traumatic brain injury and improve clinical outcomes for patients.



Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

Related Research


whatsapp--v1